This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Cubist Reports Fourth Quarter And Full Year 2012 Financial Results

******************CONFERENCE CALL & WEBCAST INFORMATION******************

Cubist will host a conference call and live audio webcast to discuss both its fourth quarter and full year 2012 financial results, business activities and financial outlook.

WHEN: Wednesday, January 23, 2013, at 5:00 p.m. ETLIVE DOMESTIC & CANADA CALL-IN: (855) 319-7654LIVE INTERNATIONAL CALL-IN: (484) 756-4327Attendee Passcode: 83986357

24-HOUR REPLAY DOMESTIC & CANADA: (855) 859-205624-HOUR REPLAY INTERNATIONAL: (404) 537-3406

REPLAY PASSCODE:Conference ID: 83986357

CALL WILL ALSO BE BROADCAST LIVE, LISTEN ONLY, VIA THE WEB AT: www.cubist.comReplay will be available for 90 days via the Internet at www.cubist.com

**********************************************************************

About Cubist

Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address significant unmet medical needs in the acute care environment. Cubist is headquartered in Lexington, Mass. Additional information can be found at Cubist’s web site at www.cubist.com.

Cubist Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to, statements regarding (i) our unaudited fourth quarter and full-year 2012 financial results, (ii) the expected timing of our Phase 3 clinical trial data readouts and NDA filing for ceftolozane/tazobactam (CXA-201) in cUTI and cIAI, (iii) the expected timing of our NDA filing for surotomycin (CB-315) in CDAD, (iv) the expected benefits from QIDP designation for ceftolozane/tazobactam and surotomycin, (v) our belief in the blockbuster potential of ceftolozane/tazobactam, (vi) the expected timing of beginning our Phase 3 program in ventilator-associated bacterial pneumonia for ceftolozane/tazobactam and Phase 3 efficacy trials for bevenopran (CB-5945) and (vii) our Building Blocks of Growth five-year goals, are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.

Such risks and uncertainties include: the risk that our final fourth quarter and 2012 full year audited financial results will differ materially from our expected results disclosed in this release; our ability to continue to grow revenues from the sale of CUBICIN; the ability of our third-party suppliers to produce and deliver adequate amounts of our products and product candidates; competition from generic drug companies such as Teva and Hospira; our ability to successfully market and sell ENTEREG; our ability to successfully develop, gain marketing approval for and commercially launch ceftolozane/tazobactam and our other product candidates for their planned indications and on the timelines that we expect; our ability to in-license or acquire new products and product candidates; our ability to achieve and manage our growth in our business; and those additional factors discussed in our most recent quarterly report on Form 10-Q filed with the Securities and Exchange Commission. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. These forward-looking statements speak only as of the date of this document, and we undertake no obligation to update or revise any of these statements.

 
CUBIST PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
UNAUDITED
(in thousands)
       
December 31, December 31,
2012 2011
ASSETS
Cash, cash equivalents and investments $ 979,396 $ 867,695
Accounts receivable, net 93,467 87,800
Inventory 79,440 75,300
Property and equipment, net 166,465 168,425
Deferred tax assets, net 14,190 16,252
In-process research and development 272,700 311,400
Other assets   326,727   356,643
 
Total assets $ 1,932,385 $ 1,883,515
 
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable and accrued expenses $ 209,236 $ 177,378
Deferred tax liabilities, net 103,081 139,237
Deferred revenue 40,875 31,524
Contingent consideration 189,213 248,234
Debt and other liabilities, net   399,232   487,285
Total liabilities   941,637   1,083,658
 
Total stockholders' equity   990,748   799,857
 
Total liabilities and stockholders' equity $ 1,932,385 $ 1,883,515
 
 
CUBIST PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
UNAUDITED
(in thousands, except share and per share data)
                   
Three months ended Twelve months ended
December 31, December 31,
2012 2011 2012 2011
 
Revenues:
U.S. CUBICIN product revenues, net $ 216,041 $ 190,113 $ 809,200 $ 698,837
U.S. ENTEREG product revenues, net   10,941     2,530     40,171     2,530  
Total U.S. product revenues, net 226,982 192,643 849,371 701,367
International product revenues 14,478 10,833 50,454 36,658
Service revenues 3,705 3,705 23,249 6,725
Other revenues   754     5,724     3,285     9,222  
Total revenues, net   245,919     212,905     926,359     753,972  
 
Costs and expenses:
Cost of product revenues 61,474 48,931 230,057 172,864
Research and development 89,154 56,075 277,729 184,533
Impairment of in-process research and development 38,700 - 38,700 -
Contingent consideration (36,017 ) 6,554 (29,021 ) 91,537
Selling, general and administrative 47,333 48,774 171,788 163,228
Restructuring charges   -     9,279     -     9,279  
Total costs and expenses   200,644     169,613     689,253     621,441  
 
Operating income 45,275 43,292 237,106 132,531
 
Other income (expense), net (7,553 ) (7,161 ) (37,510 ) (27,742 )
       
Income before income taxes 37,722 36,131 199,596 104,789
 
(Benefit) provision for income taxes (115 ) 29,313 45,521 71,766
       
Net income $ 37,837   $ 6,818   $ 154,075   $ 33,023  
 
Basic earnings per share $ 0.59 $ 0.11 $ 2.42 $ 0.54
Diluted earnings per share $ 0.51

1

 

$ 0.11 $ 2.10

1

 

 

$ 0.52
 
Shares used in calculating:
Basic earnings per share 64,504,616 62,108,586 63,766,209 60,839,128
Diluted earnings per share 82,030,774 64,499,442 81,444,658 62,937,141
 

1 Includes add back of interest expense, debt issuance costs and debt discount amortization on 2.50% notes to income, net of tax effect

 
 
CUBIST PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME - NON-GAAP
UNAUDITED
(in thousands, except share and per share data)
                       
Three months ended Twelve months ended
Reconciliation of GAAP net income to non-GAAP proforma net income December 31, December 31,
2012 2011 2012 2011
 
GAAP net income $ 37,837 $ 6,818 $ 154,075 $ 33,023
 
ENTEREG intangible asset amortization 4,565 937 18,331 937
 
ENTEREG inventory step-up 1,705 - 4,033

 

-
 
Impairment of in-process research and development 38,700 - 38,700 -
 
Contingent consideration (36,017 ) 6,554 (29,021 ) 91,537
 
Non-cash debt discount amortization 3,800 4,739 17,244 18,446
 
Loss on extinguishment of 2.25% notes 738 - 4,467 -
 
Expenses related to the acquisition of Adolor - 10,263 5,393 10,263
 
Restructuring charge - 9,279 - 9,279
 
Loss on disposal of property and equipment - - 3,248

 

-
 
Reversal of reserve for uncertain tax positions - - (10,961 ) -
 
Non-cash tax adjustment (14,090 ) 9,613 6,797 29,996
       
Non-GAAP pro forma net income $ 37,238   $ 48,203 $ 212,306   $ 193,481
 
Non-GAAP basic earnings per share $ 0.58 $ 0.78 $ 3.33 $ 3.18
Non-GAAP diluted earnings per share $ 0.48

1

 

$ 0.60

1

 

$ 2.65

1

 

$ 2.46

1

 

 
Shares used in calculating:
Non-GAAP basic earnings per share 64,504,616 62,108,586 63,766,209 60,839,128
Non-GAAP diluted earnings per share 82,326,462 83,472,974 83,406,931 81,910,673
 
¹ Includes add back of interest expense and debt issuance costs on 2.25% notes and 2.50% notes to income, net of tax effect
 
 
CUBIST PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME - NON-GAAP
UNAUDITED
(in thousands)
                 
Three months ended Twelve months ended
Reconciliation of GAAP operating income to non-GAAP adjusted operating income December 31, December 31,
2012 2011 2012 2011
 
Operating income $ 45,275 $ 43,292 $ 237,106

 

$ 132,531
 
ENTEREG intangible asset amortization 4,565 937 18,331 937
 
ENTEREG inventory step-up 1,705 - 4,033 -
 
Impairment of in-process research and development 38,700 - 38,700 -
 
Contingent consideration (36,017 ) 6,554 (29,021 )

 

91,537
 
Expenses related to the acquisition of Adolor - 10,263 5,393 10,263
 
Restructuring charges - 9,279 - 9,279
       
Non-GAAP adjusted operating income $ 54,228   $ 70,325 $ 274,542   $ 244,547
 
 
CUBIST PHARMACEUTICALS, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
UNAUDITED
(in thousands, except share and per share data)
                   
 
Three months ended Twelve months ended
December 31, December 31,
2012 2011 2012 2011
Reconciliation of GAAP basic earnings per share to non-GAAP basic earnings per share
 
Non-GAAP basic net income - from table above $ 37,238   $ 48,203 $ 212,306 $ 193,481
 
GAAP and Non-GAAP basic shares   64,504,616     62,108,586   63,766,209   60,839,128
 
GAAP basic earnings per share $ 0.59 $ 0.11 $ 2.42 $ 0.54
Non-GAAP adjustments - from table above   (0.01 )   0.67   0.91   2.64
Non-GAAP basic earnings per share $ 0.58   $ 0.78 $ 3.33 $ 3.18
 
Reconciliation of GAAP diluted earnings per share to non-GAAP diluted earnings per share
 
Non-GAAP basic net income - from table above $ 37,238 $ 48,203 $ 212,306 $ 193,481
Non-GAAP dilutive adjustments   2,079  

1

  1,902

1

  9,039

1

  7,975

1

Non-GAAP diluted net income $ 39,317   $ 50,105 $ 221,345 $ 201,456
 
GAAP diluted shares 82,030,774 64,499,442 81,444,658 62,937,141
Non-GAAP dilutive adjustments   295,688  

2

  18,973,532

2

  1,962,273

2

  18,973,532

2

Non-GAAP diluted shares   82,326,462     83,472,974   83,406,931   81,910,673
 
GAAP diluted earnings per share $ 0.51 $ 0.11 $ 2.10 $ 0.52
Non-GAAP dilutive adjustments   (0.03 )   0.49   0.55   1.94
Non-GAAP diluted earnings per share $ 0.48   $ 0.60 $ 2.65 $ 2.46
 
 
1 Includes add back of interest expense and debt issuance costs on 2.25% notes and 2.50% notes to income, net of tax effect
2 Weighted average shares issued on full conversion
 
 




Stock quotes in this article: CBST 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs